Vor Biopharma Inc. (VOR): restructuring charge — Vor Bio winds down operations, cuts 95% of staff, and explores sale or merger

Vor Biopharma Inc.

Board approved wind-down of clinical and manufacturing operations; workforce reduced by 147 employees (~95%).
Total wind-down cost estimated at $19.3M including $10.9M in severance and $4.4M asset write-down.
CFO Han Choi and CSO Tirtha Chakraborty terminated without cause effective May 16, 2025; severance of ten months salary.
Company exploring strategic alternatives including asset sale, licensing, merger, or sale of the company.
Cash, cash equivalents and marketable securities were $91.9M as of Dec 31, 2024; Q1 results due May 14.

item 2.05 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Han Choi

Chief Financial Officer

VOR · Vor Biopharma Inc.

Effective: 2025-05-16
Filed: May 8, 2025, 7:59 PM ET

on May 8, 2025, the Company terminated the employment of Han Choi as Chief Financial Officer and Tirtha Chakraborty, PhD as Chief Scientific Officer and Head of Technical Operations, effective as of May 16, 2025 (the “Separation Date”), without cause.

Departed

Tirtha Chakraborty

Chief Scientific Officer and Head of Technical Operations

VOR · Vor Biopharma Inc.

Effective: 2025-05-16
Filed: May 8, 2025, 7:59 PM ET

on May 8, 2025, the Company terminated the employment of Han Choi as Chief Financial Officer and Tirtha Chakraborty, PhD as Chief Scientific Officer and Head of Technical Operations, effective as of May 16, 2025 (the “Separation Date”), without cause.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Han Choi was terminated as Chief Financial Officer at Vor Biopharma Inc..

Action: terminated
Role: Chief Financial Officer

Exact text from the filing

on May 8, 2025, the Company terminated the employment of Han Choi as Chief Financial Officer and Tirtha Chakraborty, PhD as Chief Scientific Officer and Head of Technical Operations, effective as of May 16, 2025 (the “Separation Date”), without cause.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Tirtha Chakraborty was terminated as Chief Scientific Officer and Head of Technical Operations at Vor Biopharma Inc..

Action: terminated
Role: Chief Scientific Officer and Head of Technical Operations

Exact text from the filing

on May 8, 2025, the Company terminated the employment of Han Choi as Chief Financial Officer and Tirtha Chakraborty, PhD as Chief Scientific Officer and Head of Technical Operations, effective as of May 16, 2025 (the “Separation Date”), without cause.

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Vor Biopharma Inc. announced a restructuring with charges of approximately $19.3 million affecting clinical and manufacturing operations (147 full-time employees, or approximately 95% of the Company’s current employee base).

Type: restructuring
Charge: approximately $19.3 million
Affected area: clinical and manufacturing operations
Headcount: 147 full-time employees, or approximately 95% of the Company’s current employee base

Exact text from the filing

full-time employees, or approximately 95% of the Company’s current employee base (the “Wind Down”). The total costs related to the Wind Down are estimated to be approximately $19.3 million. The Company estimates that it will incur approximately $3.5 million in contract termination and other costs related to the discontinuation of its clinical trials, approximately

View on SEC.gov

7 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Vor Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-115554

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.